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Abstract
Angiopoietin-like protein 4 (ANGPTL4) is a lipoprotein lipase inhibitor that is involved in lipid metabolism and angiogenesis. Animal studies have sug-
gested that the ANGPTL4 protein is modulated by the gut microbiota, possibly through increased concentrations of SCFA, such as C4, found in whole-fat
milk or as a result of fermentation of inulin. This study investigated whether a standardised diet either high in fat content or supplemented with inulin
powder would increase plasma ANGPTL4 in overweight men and whether this increase was mediated through a compositional change of the gut micro-
biota. The study had a crossover design with three arms, where participants were given a standardised isoenergetic diet supplemented with inulin powder,
whole-fat milk or water (control). Plasma and urine samples were collected before and after each intervention period. Faecal samples and adipose tissue
biopsies were collected after each intervention period. The study included twenty-one participants of whom eighteen completed the study. The dietary
interventions did not change ANGPTL4 plasma concentration, nor was plasma ANGPTL4 associated with plasma lipids, TAG or NEFA concentration.
The relative abundance of biﬁdobacteria following the inulin diet was higher, compared with the control diet. However, the changes in microbiota were not
associated with plasma ANGPTL4 and the overall composition of the microbiota did not change between the dietary periods. Although weight was main-
tained throughout the dietary periods, weight was negatively associated with plasma ANGPTL4 concentration. In the adipose tissue, ANGPTL4 expression
was correlated with leptin expression, but not with hypoxia-inducible factor 1α (HIF-1α) expression.
Key words: Angiopoietin-like protein 4: Lipid metabolism: Lipoprotein lipase: Obesity: Gut microbiome
Dysregulation of TAG and fatty acid metabolism increases the
risk of CVD and type 2 diabetes(1) and stringent regulation of
lipid metabolism is a prerequisite for maintaining metabolic
health. Angiopoietin-like protein 4 (ANGPTL4) is a lipoprotein
lipase inhibitor that regulates lipidmetabolism and storage(2) and
as such ANGPTL4 is a potential target for interventions to
modify the risk of developing obesity-associated diseases.
ANGPTL4 is expressed in several tissues in humans,
including the liver, adipose tissue and intestine(3). The protein
is negatively associated with TAG concentration in animal
models(4,5). In humans, plasma ANGPTL4 is positively asso-
ciated with concentrations of NEFA and increased lipoly-
sis(6,7), while carriers of an ANGPTL4 loss-of-function
mutation have lower TAG concentration than non-carriers(8,9).
Abbreviations: %E, percentage energy; ANGPTL4, angiopoietin-like protein 4; HIF-1α, hypoxia-inducible factor 1α.
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Additionally, ANGPTL4 is a regulator of angiogenesis and
mediator of the effect of hypoxia in the adipose tissue,
which inﬂuences the lipid-storing capacity of adipose tissue(2).
ANGPTL4 can be regulated by diet(6,10,11). A short-term
(3 d) human study observed an up-regulation of plasma
ANGPTL4 in response to a high-fat diet (69 % energy
(E%) as fat), a very low-energy diet (471 kcal/d; 1971 kJ/d)
and fasting(6), which suggests that an increased concentration
of NEFA in the bloodstream up-regulates expression of
ANGPTL4. This up-regulation has been shown in vitro
as expression of ANGPTL4 is up-regulated in response
to exposure to fatty acids, including 16 : 0, 18 : 1n-9 and
20 : 4n-6 in cell studies(12,13).
Regulating ANGPTL4 by diet-induced modiﬁcations of the
gut microbiota offers the potential of indirectly modulating
ANGPTL4 without intake of excessive amounts of fat or by
extreme fasting. Conventionalisation of germ-free mice has
shown down-regulation of intestinal ANGPTL4 expression(14)
whereas Lactobacillus paracasei F19 has been shown to increase
concentrations of circulating ANGPTL4 in mice(10). The
observed up-regulation is probably caused by an increase in
the production of SCFA, particularly C4, which has been
shown to increase ANGPTL4 expression in vitro(15). An in
vivo up-regulation of C4 could be induced by increasing the
relative proportion of C4-producing bacteria, such as the
Roseburia species(16), by supplying prebiotics in the diet(17).
Collectively, the evidence suggests that ANGPTL4 is an
important regulator of lipid metabolism, with potential conse-
quences for health, and that dietary interventions may alter cir-
culatory ANGPTL4. However, it is unclear whether moderate
dietary interventions of intermediate duration in human sub-
jects can modify ANGPTL4. Further, the role of the gut
microbiota and adipose tissue in regulation of ANGPTL4
has not been examined in humans.
Thus, the objective of the study was to investigate whether a
standardised diet either high in milk fat or supplemented with
inulin powder would increase plasma ANGPTL4 in over-
weight men and whether this increase was mediated through
a compositional change of the gut microbiome.
Methods
Study design
Thestudywasa randomised, controlled, crossover studywith three
21 d interventionperiods.The interventionperiodswere separated
byawash-outperiodof at least 21 d.Theparticipants completedan
investigation day at the start and end of each intervention period as
well as a brief visit 24 h after the start of each intervention period.
All study visits were carried out at the Department for Nutrition,
Exercise and Sports, Copenhagen University, Denmark.
Recruitment commenced August 2013 and was completed in
January 2014. The study was completed in July 2014.
This study was conducted according to the guidelines laid
down in the Declaration of Helsinki and all procedures involv-
ing human participants were approved by the Regional Ethical
Committee of Copenhagen (no. H-3-2013-086). Written
informed consent was obtained from all subjects.
The study was registered at www.clinicaltrials.gov with the
identiﬁer NCT01913678 and the Danish Data Protection
Agency (2007-54-0269).
Subjects
The inclusion criteria required the participants to be men,
healthy, aged 23–45 years, have a BMI of 25–35 kg/m2 and
a body fat percentage >20 %. Exclusion criteria included the
presence of chronic diseases, such as diabetes, CVD, irritable
bowel syndrome, colitis ulcerosa, Crohn’s disease and other
chronic diseases likely to affect the outcomes of the study,
as well as milk allergy or lactose intolerance, intolerance
towards inulin, elevated fasting glucose (≥7·0 mmol/l or non-
fasting glucose ≥11 mmol/l), the use of antibiotics 2 months
before commencement of study, the use of dietary supple-
ments including multivitamins during the entire study period,
smoking, excessive physical activity (>10 h of strenuous phys-
ical activity per week), use of prescription medicine, which
could affect the results of the present study including systemic
glucocorticoids and the use of lipid-lowering agents or medica-
tion with contraindications for a high-fat diet, blood pressure
>140/90 mmHg, blood donation <1 month before study
commencement and during the study period, simultaneous
participation in other clinical studies or the inability, physically
or mentally, to comply with the procedures required by the
study protocol as evaluated by the study staff.
Participants were recruited through local newspapers and
ﬂyers at educational institutions in the Copenhagen area.
Informed consent was signed by all participants before the
commencement of any study procedures. Subsequently, the
participants completed a screening visit to assess biological
and anthropometric inclusion and exclusion criteria. Weight,
height, blood glucose, body fat percentage and blood pressure
were measured at the screening. Potential participants that ful-
ﬁlled the inclusion and exclusion criteria were invited to par-
ticipate in the study.
Interventions
The diets were isoenergetic and participants were on one of
two energy levels (13 or 15 MJ/d) according to the BMR,
which was calculated based on age, sex, height, weight using
the Schoﬁeld equation for men >18 years(18) and adjusted
for self-reported physical activity level. The participants were
instructed to weigh themselves weekly to ensure weight stabil-
ity and additionally to register their intake of ﬂuids, physical
activity level and bowel movements. If weight changes above
0·5 kg/week occurred, the diet was adjusted to match the
energy requirement of the individual.
The diets were composed of typical Danish dishes. The diet-
ary items for each day were repeated in modules of 4 d, so that
each module was repeated four or ﬁve times during the 21 d of
intervention. Relative macronutrient composition was held
constant between energy requirement levels. The diets were
designed so that the high-inulin diet differed only from the
control diet in the carbohydrate type, with 13–15 g of inulin
ﬁbre added to the high-inulin diet (high-inulin diet E%:
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carbohydrate: 55 %, fat: 35 %, protein: 15 %). The total carbo-
hydrate energy percentage was identical between the two diets
(control E%: carbohydrate: 55 %, fat: 35 %, protein: 15 %).
The high-dairy diet differed from the control diet in fat energy
percentage and type (high-dairy diet E%: carbohydrate: 45 %,
fat: 40 %, protein: 15 %). Protein quantity and quality were
similar in the three dietary periods and the source of ﬁbre
was identical between groups besides the inulin supplement
in the high-inulin group.
The participants were provided with all dietary items includ-
ing beverages twice weekly throughout the three intervention
periods. They were instructed not to consume anything
besides the dietary items provided except for habitual intake
of non-energy beverages (water, coffee, tea and artiﬁcially
sweetened drinks). During the wash-out periods, the partici-
pants were asked to maintain their habitual dietary intake
and level of physical activity. Depending on the energy require-
ment of the participants, 13 or 15 g of ﬂavourless and odour-
less Inulin HPX®, designated safe for consumption
(BENEO-Orafti, Alsiano A/S) were dissolved in 500 ml of
90°C warm water until the powder had dissolved.
Subsequently, the solution was cooled at 5°C overnight.
Two drops of apple aroma were added to ensure that there
was no difference in taste of the solutions. Supplemental
water was treated identically to the inulin solution, without
the addition of inulin powder. In the milk intervention period,
the participants were given a minimum of 1 litre of Lærkevang
whole-fat milk (Arla A/S) based on individual energy levels.
Outcome measures
The primary outcome was changes in plasma ANGPTL4
concentration. The secondary outcomes were changes in
blood lipid proﬁle, characterisation of changes in faecal
microbiota composition including changes in faecal SCFA
content, changes in resting energy expenditure and lipid oxi-
dation, changes in lipid and glucose metabolism, and
ANGPTL4 mRNA expression as well as gene expression
of proteins related to obesity and hypoxia in adipose tissue.
The secondary/exploratory outcomes also included a test
of the effect of faecal water on ANGPTL4 expression in a
human intestinal cell line. However the cells were not viable
at relevant physiological concentrations and the assay was
abandoned.
The participants were required to arrive at the department
after a 12 h fast and to abstain from alcohol and strenuous
physical activity for 48 h prior to the investigation days. The
participants were asked to drink 500 ml of water during the
fasting period. Additionally, they were asked to arrive via a
transportation mode that did not require physical exertion.
Upon arrival at the department, the participants were asked
to void their bladder and were weighed. Their medical history
and changes since their last visit were recorded.
Respiratory exchange was measured in a ventilated hood
system (Jaeger Oxycon Pro Ventilated Hood system;
Intramedic A/S) following 30 min of rest in supine position.
Measurements were recorded over 25 min and were repeated
once. The system was calibrated in the morning, prior to the
measurements and between measurements. The accuracy of
the ventilated hood was validated by an alcohol combustion
test on a weekly basis with a CV of 1·5 %.
Body fat percentage was estimated with a hand-held bioimpe-
dance device at screening (Tanita A/S). Participants were asked
to remove all metals on their upper body and to stand erect,
holding the device at shoulder height. Data on age, sex, height
and weight were entered into the device prior to measurements.
Dual-energy X-ray absorptiometry scans (Lunar Prodigy, GE
Healthcare Danmark A/S) were performed once on the ﬁrst
day of the ﬁrst dietary period. The participants were asked to
remove all metal from their body and were scanned in the
supine position in their underwear. They were instructed to lie
still while being scanned. Weight was recorded in the fasted
state, after voiding of the bladder, on a bathroom scale
(Lindeltronic 8000S; Lindells), with the participant in their
underwear. The participants were asked to distribute their
weight evenly on both feet. Weight was recorded with an accur-
acy of 0·1 kg. Height was recorded on a wall-mounted stadi-
ometer. The participant was asked to remove their shoes,
stand erect with their heels together, arms to the side, and look-
ing straight ahead. The participant was asked to take a deep
breath and the measurement was performed before exhaling.
Height was recorded with an accuracy of 0·5 cm.
Blood pressure and pulse were measured with an automated
sphygmomanometer after a minimum of 15 min rest in the
supine position. The measurement was repeated. To ensure
accuracy of the measurements, blood pressure was assessed
again if the difference between measurements exceeded 5
mm Hg for either systolic or diastolic blood pressure.
Faecal samples were collected for ﬁve consecutive days at
the end of each intervention period. The participants were
asked to collect all faecal matter in the period and to either
store the samples on ice at home or deliver them to the depart-
ment following collection. A small aliquot of the faecal sam-
ples was immediately frozen at −80°C for later analysis of
the microbiota composition. Subsequently, all remaining sam-
ples were frozen until further treatment. The samples were
then thawed at 5°C overnight. MilliQ water was added 1:1
(w/w) and the samples were homogenised with a rod blender
and pooled with samples within participant and period. The
pooled samples were frozen immediately at −80°C until ana-
lysis of NEFA.
Urine samples were collected over 24 consecutive hours at
the start and end of each intervention period. The participants
started urine collection in the morning on day 1 of the collec-
tion after voiding of the bladder. Collection was completed
with the ﬁrst voiding of the bladder on day 2 of collection.
The participants were asked to take three para-aminobenzoic
acid tablets of 80 mg during the collection period to monitor
compliance. At the department, the urine samples were
pooled, aliquoted and frozen at −80°C until analysis.
Fasting blood samples were collected at the ﬁrst and last
investigation day in all three periods. Additionally, a postpran-
dial sample was collected 24 h after commencement of the
intervention period. The samples for glucose analysis were col-
lected in ﬂuoride-coated vials. Samples designated for analysis
of the lipid proﬁle, C-reactive protein and insulin were
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collected in dry vials and allowed to stand for 20 min until
coagulation. Samples for ANGPTL4 analysis were collected in
EDTA-coated vials. All samples were centrifuged at 2500 g
for 10 min and transferred to storage at −80°C until analysis.
An adipose tissue biopsy from the subcutaneous abdomen
was performed upon completion of each intervention period.
The biopsies were voluntary. Adipose tissue biopsies were per-
formed according to standard operating procedure by trained
medical staff. The area of skin was anaesthetised prior to injec-
tion of the biopsy needle (Pelomi Medical). The adipose sam-
ple was washed with sterile saline and blood and connective
tissue was removed. Following cleaning, the sample was frozen
immediately at −80°C in liquid N2.
Sample size and randomisation
The sample size determination was based on changes in
plasma ANGPTL4 concentration reported in a previous
study(6). The minimal difference in ANGPTL4 concentration
was reported to be 3·3 ng/ml and the duration of the interven-
tion period was 3 d. During this 21-d intervention, a minimal
difference of at least 5 ng/ml was deemed realistic. Including
twenty participants (eighteen completers) would provide 80 %
power to detect this difference, allowing for a 10 % dropout
at a 0·05 signiﬁcance level. During the intervention, three parti-
cipants dropped out and therefore an additional participant was
recruited for the study (in accordance with the protocol).
The participants were randomly allocated to the sequence of
the diet periods. The allocation sequence was computer-
generated using randomly permuted blocks. The allocation
of sequence was performed by a person that did not perform
any measurements or tasks in the study, whereas another per-
son produced the diets. A third person was responsible for
including participants and for data analysis, and was blinded
to the diet period sequence as well as the coding of the inulin
and control diet. The allocation sequence was generated before
commencement of enrolment and was not changed through-
out the study. The participants were blinded to the inulin
and control diet as they were visually identical, but due to
the nature of the milk intervention, the participants and
study staff were not blinded to this intervention. All study per-
sonnel that performed measurements were blinded to the inu-
lin intervention throughout the study. Data were validated with
double entries, performed individually by two members of the
study staff. Statistical analysis was performed for all combina-
tions of codes and documented before the codes were broken.
Analyses
Glucose concentration at screening was measured using a sin-
gle drop of blood from the ﬁnger tip of the participant and
assessed with the Hemocue Glucose 201+ System
(HemoCue AB). The participants were not required to be fast-
ing and therefore inclusion was based on either a fasting blood
glucose concentration of <7·0 mmol/l or a postprandial blood
glucose concentration of <11·0 mmol/l.
The procedure for ANGPTL4 analysis has been described
elsewhere(11) and was performed with minor modiﬁcations.
Brieﬂy, plates were coated with anti-human ANGPTL4 anti-
body (RnD Systems, catalogue no. AF3485) diluted in ﬁlter-
sterile PBS to reach a concentration of 0·2 mg/ml. The plates
were then incubated at 5°C overnight on a rotating platform.
The following morning, the plate was washed four times
with washing buffer (PBS with a pH of 7·2–7·4, milliQ
water and Tween®20) and incubated for 1 h with 300 µl of
blocking solution in each well (10 % bovine serum albumin
(BSA) in milliQ water). Samples were diluted 50-fold in diluent
(RnD Systems, catalogue no. DY995). Recombinant human
ANGPTL4 protein (RnD Systems, catalogue no. 3485-AN)
was likewise diluted in diluent to produce a standard curve
of 0, 0·3, 0·6, 0·9, 1·2, 1·5, 1·8 and 2·1 ng/ml. After four
washes, the plates were incubated with 100 µl of sample per
well and standard curve solutions for 2 h on a rotating plat-
form before being washed four times and incubated with
100 µl of detection antibody solution (50 µg/ml solution of
diluent and biotinylated anti-human ANGPTL4 antibody,
RnD Systems catalogue no. BAF3485) for an additional 2 h.
Subsequently, the plates were washed four times and incubated
with a streptavidin horseradish peroxidase solution (PBS, 10 %
BSA solution and streptavidin horseradish peroxidase) for
20 min on a rotating platform. Substrate (tetramethylbenzi-
dine) was added after four washes and the plates were incu-
bated for 8 min and subsequently the reaction was stopped
with 50 µl of H2SO4. Optical density was then determined
at 450 nm with a microplate reader (Spectra Rainbow; SLT
Labinstruments).
Analysis of the microbiota composition was performed on a
total of ﬁfty-six faecal samples. Microbial DNA was extracted
using a NucleoSpin soil kit (Macherey-Nagel) according to the
manufacturer’s instructions. PCR-based library formation,
sequencing (Illumina MiSeq) and taxonomy assignment were
performed as described in Holm et al.(19). The microbiota
composition was tested for differences due to diets or changes
in plasma ANGPTL4 concentration from before and after
intervention. Data analysis was performed in R v3.1.2 using
the metagenomeSeq(20), PhyloSeq(21), Vegan: Community
Ecology Package(22) and GGplot2(23) packages. The analysis
was performed using ﬁltered and normalised data, except for
α diversity, which was calculated using raw, unﬁltered data.
The data were ﬁltered by removing operational taxonomic
units represented in fewer than three of the ﬁfty-six samples
or with a relative abundance across all samples smaller than
0·005 %. Read counts were normalised with metagenomeSeq
using a cumulative-sum scaling in which raw counts were
divided by the cumulative sum of counts up to a particular
quantile. On average the dataset contained 32237 and 27602
sequences per sample before and after ﬁltering, respectively.
Plasma samples from the beginning of each intervention
period, 24 h after commencement of the intervention
periods and after the periods were analysed for total NEFA
concentration with the PENTRA 400 (HORIBA) (intra-serial
CV 1·7 %). CV for glucose, cholesterol, HDL-cholesterol,
LDL-cholesterol, TAG and insulin was 1·1, 0·4, 1·8, 1·4,
4·0, 3·9 and 7·1 %, respectively. Faecal homogenates, and
plasma and urine samples were analysed for quantiﬁcation
of individual fatty acids at the end of each intervention.
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Data from faecal samples were adjusted for the total weight of
the faecal collection.
Individual NEFA were quantiﬁed in bioﬂuids (1 ml of urine
and 1·8 ml of plasma) using the ethyl chloroformate free fatty
acid (ECF-FFA) method(24) and in faeces (0·1 g) with the
modiﬁcation from Amer et al(25). 2H-labelled internal standards
were added to the samples: 3 : 0, 6 : 0, and 16 : 0 to a ﬁnal con-
centration of 0·3 mg/ml; C4 to 0·6 mg/ml; 5 : 0, 6 : 0, 8 : 0,
10 : 0, 12 : 0, 14 : 0 and 15 : 0 to 0·03 mg/ml; 17 : 0 to 0·15
mg/ml and 18 : 0 to 0·1 mg/ml. 15 : 0 concentration was
too low to quantify. ECF, C5H5N, 18 : 2n-6, and 18 : 3n-3
standards were obtained from Sigma-Aldrich Chemie
GmbH; anhydrous C2H6O, 3 : 0, 4 : 0, isobutyric acid, isovale-
ric acid, 2-methyl butyric acid, 5 : 0, 7 : 0, 9 : 0 and 11 : 0 stan-
dards, 3 : 0 (D5, 98 %), and 6 : 0 (D11, 98 %) internal
standards were obtained from Sigma-Aldrich Chemie
GmbH. 6 : 0, 8 : 0, 10 : 0, 12 : 0, 13 : 0, 14 : 0, 15 : 0, 16 : 0,
18 : 0 and 18 : 1n-9 standards were obtained from Fluka
Chemie GmbH. C4 (D7, 98 %), 8 : 0 (D15, 98 %), 10 : 0
(D19, 98 %), 12 : 0 (D23, 98 %), 14 : 0 (D27, 98 %), 16 : 0
(D31, 98 %) and 18 : 0 (D35, 98 %) internal standards were
obtained from Cambridge Isotope Laboratories, Inc., and
the 15 : 0 (D29, 99·2 %) internal standard from CDN iso-
topes. Chloroform was obtained from Chem Solute, and
NaOH from J. T. Baker. Ultrapure water came from a
Milli-Q system (Millipore SAS), and anhydrous Na2SO4 was
purchased from Merck.
NMR-based metabolomics was performed on a total num-
ber of 117 urine samples. 1H NMR spectroscopy was per-
formed at 298 K on a Bruker Avance III 600 spectrometer,
operating at a 1H frequency of 600·13 MHz, and equipped
with a 5-mm 1H TXI probe (Bruker BioSpin). Standard one-
dimensional spectra were acquired using a single 90° pulse
experiment with a relaxation delay of 5 s. Water suppression
was achieved by irradiating the water peak during the relax-
ation delay, and a total of sixty-four scans were collected
into 32 K data points spanning a spectral width of 12·15
parts per million (ppm). Urine samples were thawed at room
temperature, vortexed for 30 s, and centrifuged at 10 000 g
for 5 min, 500 µl of supernatant were transferred to a 5 mm
NMR tube and mixed with 100 µl of 0·75 M-PBS containing
0·5 % sodium trimethylsilyl propionate-d4 (TSP) in
2H-labelled water. Prior to Fourier transformation the data
were multiplied by a 0·3 Hz line-broadening function. The
proton NMR spectra were phase and baseline corrected manu-
ally using Topspin 3.2 (Bruker Biospin). All 1H spectra were
initially referenced to the TSP signal at 0 ppm. After acquisi-
tion NMR spectra were proﬁled using Chenomx NMR Suite
8.1 (Chenomx). Ten metabolites were integrated and quanti-
ﬁed using the Proﬁler module in the Chenomx NMR Suite.
Each metabolite was manually checked in all samples in
order to ensure a good ﬁtting. As urine was collected over a
24-h period, the concentration of each metabolite is repre-
sented in units of mM/mM creatinine per 24 h.
The RNA was extracted from the adipose tissue samples
using the RNeasy Lipid Tissue Mini kit (Qiagen Nordic).
The adipose tissue samples were disrupted and homogenised
with the use of the GentleMACS™ dissociator (Miltenyi
Biotec Norden AB). The frozen samples together with lysis
buffer (QIAzol lysis reagent) were added to the
GentleMACS™ M tubes and the homogenisation was done
according to the manufacturer’s instructions. After a short
incubation at room temperature, the samples were centrifuged.
Subsequently, the RNeasy Lipid Tissue Mini kit protocol was
followed. Centrifugation time was modiﬁed and increased to
30 min at step 5, 30 s at step 7, 9 and 10 and 2·5 min at
step 11 in the manufacturer’s protocol. Successful tissue hom-
ogenisation and extraction were ensured with the measure-
ment of RNA quality and concentration (Nanodrop 1000
spectrophotometer; Thermo Fischer Scientiﬁc). cDNA syn-
thesis was performed according to protocol with the use of
TaqMan® Reverse Transcription Reagents from Invitrogen™
(Life Technologies Europe BV). A concentration of 0·4 µg
was used for a total of 20 µl RT reaction mix. The reverse
transcriptase reaction mix was added to a ninety-six-well reac-
tion plate together with the RNA solution for each sample and
sealed with MicroAmp® Optical Caps. The plate was placed in
the Applied Biosystems RT PCR 7900HT system. The plate
was heated to 25°C for 10 min, incubated at 48°C for 30
min and ﬁnally stopped by heating at 95°C for 5 min.
Quantitative PCR was carried out with the use of TaqMan®
Gene Expression Assays for ANGPTL4 (assay no.:
Hs01101127_m1), hypoxia-inducible factor 1α (HIF-1a)
(assay no.: Hs00153153_m1), glyceraldehyde-3-phosphate
dehydrogenase (GADPH) (assay no.: Hs02758991_g1) and
LEP (assay no.: Hs00174877_m1) (Life Technologies
Europe BV), according to protocol. The ﬁnal reaction mix
was loaded to a ninety-six-well plate. Four replicates were
made for each sample and a fast run was done with the
Applied Biosystems RT PCR 7900HT system (Applied
Biosystems International Inc.). GAPDH was included as a ref-
erence gene.
Statistical methods
Statistical analyses were performed using R version 3.1.2 (The
R Foundation for Statistical Computing, 2014). All dependent
variables were controlled for normal distribution by histo-
grams and the Shapiro–Wilk test for normality. Variables
that were not normally distributed were transformed.
ANGPTL4 plasma concentrations were not normally distribu-
ted and were log-transformed for analyses of associations.
Differences between treatments were analysed in a
mixed-effect model with participant as a random-effects fac-
tor. The models were adjusted for weight and age, and were
validated with residual plots and normal quantile plots. The
active treatments (the high-inulin and high-dairy diets) were
compared with the control diet individually. The mRNA of
the adipose tissue was analysed with the use of the compara-
tive CT method. Ampliﬁcation plots were evaluated using the
program ExpressionSuite Software version 1.0.3, the CT value
was identiﬁed and the relative quantiﬁcation calculated. To
determine if the expression of the examined genes was inter-
dependent, the correlation coefﬁcient was calculated between
the ΔCT values by Pearson’s product moment correlation
coefﬁcient. To test for statistically signiﬁcant differences in
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the microbiota composition, the Adonis test based on Bray–
Curtis distance was used and metagenomeSeq for speciﬁc
operational taxonomic units and phylotypes. Statistical signiﬁ-
cance was set to P < 0·05.
Results
A total of twenty-one participants were included in the study
(Table 1). Two participants withdrew during the study due
to time constraints, and one was excluded due to lack of com-
pliance. Eighteen participants completed the three intervention
periods (nineteen participants completed the control period
and were included in the analyses and twenty participants com-
pleted the high-dairy diet period and the high-inulin diet
period).
ANGPTL4 concentration, blood lipid proﬁle, insulin or glu-
cose concentration did not change during the high-fat milk or
the inulin intervention period, compared with the control per-
iod, nor did the diets have any effect on resting energy expend-
iture and lipid oxidation (Table 2). ANGPTL4 concentrations
at the end of the intervention periods were not associated with
lipid oxidation, TAG concentration or lipid proﬁle (Table 2).
Resting energy expenditure and lipid oxidation were not asso-
ciated with ANGPTL4 concentration after adjusting for
weight (Table 2). Total plasma NEFA concentration was not
associated with plasma ANGPTL4 concentration at baseline
or at the end of the intervention periods (Table 2).
ANGPTL4 concentration was negatively associated with
weight (β−0·016 (SE 0·005), P = 0·001).
The overall faecal microbiota composition did not change
signiﬁcantly in response either to milk or to inulin, compared
with the control period (Fig. 1(a)). However, as the only
detectable differences, we observed an increase in the relative
abundance of biﬁdobacteria on the inulin diet, compared with
the control diet, while the relative abundance of Roseburia was
increased for the milk diet, compared with the inulin diet but
not compared with the control diet (Fig. 1(c)).
There were no associations with either individual NEFA,
total long-chain fatty acids or total SCFA and ANGPTL4
plasma concentration. Plasma concentrations of 16 : 0, 17 : 0,
18 : 2n-6 and 18 : 0 were signiﬁcantly higher after the milk
diet, compared with the control diet, in a model adjusted
for weight and age (Table 3). Faecal concentrations of 12 : 0
and 16 : 0 were higher for the milk diet, compared with the
control diet, whereas the concentration of 2-methyl-butyric
acid was lower after the inulin period, compared with the con-
trol period (Supplementary Tables S1 and S2). C4 excretion in
urine was not changed by either intervention diet, compared
with control (Table 4). C4 excretion in urine was not
associated with ANGPTL4 plasma concentration. Urine
concentrations of 2-hydroxyisobutyrate, citrate and HCO2
–
metabolites were higher after the milk diet compared with
the control diet, whereas inulin did not change the concentra-
tion of urinary metabolites tested (Table 5). None of the add-
itional urine metabolites tested was associated with plasma
ANGPTL4.
The ANGPTL4 expression in adipose tissue was not
affected by the diets and the correlation between HIF-1α
and ANGPTL4 mRNA did not reach signiﬁcance for either
diet (Fig. 2(a)–(c)). However, positive correlations between
ANGPTL4 and LEP mRNAs were observed in adipose tissue
after the milk and inulin diets (Fig. 2(d)–(f)). Adipose tissue
ANGPTL4 mRNA was not associated with NEFA concentra-
tion, resting energy expenditure, lipid oxidation or TAG con-
centration (Table 5).
Table 2. Study end points after the intervention periods*
(Mean values with their standard errors, and regression coefficients (β) with their standard errors)
Control Inulin diet Inulin v. control Milk diet Milk v. control
End points Mean SE Mean SE β SE P Mean SE β SE P
ANGPTL4 (ng/ml) 40·2 4·2 39·7 2·4 0·04 3·40 0·93 37·8 2·50 −1·88 3·42 1·00
Glucose (mmol/l) 5·6 0·2 5·6 0·1 −0·017 0·17 1·00 5·6 0·1 0·024 0·17 0·99
Insulin (pmol/l) 69·1 9·7 67·5 7·6 −3·85 5·60 0·93 65·9 7·9 −6·22 5·67 0·72
TAG (mmol/l) 0·96 0·07 1·27 0·23 0·062 0·08 0·68 1·32 0·28 0·100 0·08 0·65
HDL-C (mmol/l) 1·1 0·04 1·1 0·04 −0·003 0·02 1·00 1·1 0·04 0·03 0·02 0·59
LDL-C (mmol/l) 3·1 0·13 3·2 0·10 0·12 0·07 0·30 3·1 0·13 0·07 0·07 0·80
Total cholesterol (mmol/l) 4·3 0·1 4·4 0·1 0·12 0·09 0·50 4·4 0·13 0·11 0·09 0·61
Energy expenditure (kcal/d)† 1737 40 1747 43·0 8·3 28·6 0·99 1754 31·9 2·1 28·6 1·00
Lipid oxidation (kcal/d)† 806 63 773 62·4 −38 62·8 0·96 888 65·8 74·2 62·8 0·66
Total NEFA (μmol/l) 411 46 389 30·7 −23 43·6 0·97 403 24·0 −7·3 43·8 1·00
ANGPTL4, angiopoietin-like protein 4; HDL-C, HDL-cholesterol; LDL-C, LDL-cholesterol.
* Data were analysed using mixed models with participants as the random effect. Estimates for transformed variables are reported from non-transformed models. All models were
adjusted for age and weight. Significance was determined as P < 0·05.
† To obtain values in kJ/d, multiply by 4·184.
Table 1. Baseline characteristics for all participants
(Mean values with their standard errors for all included participants; n 21)
Parameter Mean SE
Age (years) 32·9 0·85
Body weight (kg) 97·2 1·40
BMI (kg/m2) 29·3 0·5
Systolic blood pressure (mmHg) 122·1 1·5
Diastolic blood pressure (mmHg) 74·0 1·0
Pulse (beats per min) 55·0 0·8
Blood glucose (mmol/l) 5·6 0·1
Insulin (pmol/l) 70·5 6·0
TAG (mmol/l) 1·27 0·09
Total cholesterol (mmol/l) 4·54 0·07
LDL-cholesterol (mmol/l) 3·2 0·1
HDL-cholesterol (mmol/l) 1·17 0·02
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Fig. 1. Diet-induced changes in the microbiota composition. (a) Non-metric multidimensional scaling (NMDS) plot using Bray–Curtis dissimilarity indices with cen-
troids based on the treatments. Relative abundance of the genera found significantly affected by the diet: Bifidobacterium (b) and Roseburia (c). Values are means,
with standard errors represented by vertical bars. * Statistically different relative abundance (adjusted P < 0·05) compared with the inulin treatment group.
Table 3. Plasma NEFA (μg/ml) after intervention periods*
(Mean values with their standard errors)
Control Inulin Milk
Fatty acid Mean SE Mean SE Mean SE Inulin v. control: P Milk v. control: P
12 : 0 1·1 0·4 0·7 0·06 0·76 0·10 0·27 0·45
14 : 0 1·8 0·2 1·7 0·2 2·17 0·15 1·00 0·52
16 : 1n-7 4·1 0·6 4·2 0·5 4·48 0·50 1·00 0·93
16 : 0 27·0 2·5 30·0 2·3 36·3 3·0 0·91 0·046
17 : 1 0·7 0·05 0·7 0·03 0·7 0·03 1·00 0·95
17 : 0 0·6 0·03 0·6 0·03 0·7 0·05 0·99 0·07
18 : 2n-6 16·5 1·6 19·2 1·5 23·7 2·4 0·80 0·02
18 : 1n-9 45·0 6·0 48·1 3·7 53·0 3·3 0·99 0·55
18 : 3n-3 1·6 0·2 1·4 0·2 1·9 0·2 0·95 0·57
18 : 0 13·5 0·8 14·7 1·0 17·9 1·6 0·95 0·02
∑ NEFA 111·1 11·5 120·7 8·6 141·3 9·7 0·95 0·12
* Data were analysed using mixed models with participants as the random effect. All models were adjusted for age and weight. Significance was determined as P < 0·05.
7
journals.cambridge.org/jns
https:/www.cambridge.org/core/terms. https://doi.org/10.1017/jns.2016.38
Downloaded from https:/www.cambridge.org/core. Copenhagen University Library, on 09 Mar 2017 at 13:12:47, subject to the Cambridge Core terms of use, available at
Discussion
A 21-d intervention with either ﬁbre or milk fat added to an
isoenergetic standardised diet did not change ANGPTL4
plasma concentrations. Microbiota analyses showed only
minor effects of the diets where inulin increased the relative
abundance of biﬁdobacteria, compared with control, and
milk increased the relative abundance of Roseburia, compared
with inulin. Regulation of ANGPTL4 expression through com-
ponents of the gut microbiota was initially proposed by Bäckhed
et al.(14), who showed that expression of ANGPTL4 was sup-
pressed in the endothelium by conventionalisation of germ-
free mice. Recently, Alex et al.(26) showed that ANGPTL4 is
produced by entero-endocrine cells, and Mattijssen et al.(27)
showed that ANGPTL4 inhibits pancreatic lipase. These ﬁnd-
ings indicate that ANGPTL4 regulates fat absorption in the
Table 4. Urine metabolites after intervention periods*
(Mean values with their standard errors)
Control Inulin Milk
Metabolite Mean SE Mean SE Mean SE Inulin v. control: P Milk v. control: P
2-Furoylglycine 0·007 0·002 0·006 0·002 0·01 0·003 0·85 0·61
2-Hydroxyisobutyrate 0·004 0·0002 0·004 0·0002 0·005 0·0002 0·10 <0·001
3-Hydroxyisovalerate 0·004 0·0004 0·004 0·0002 0·004 0·0003 0·92 0·87
Alanine 0·02 0·002 0·02 0·002 0·02 0·002 0·99 0·74
Citrate 0·1 0·03 0·2 0·03 0·2 0·04 0·19 <0·001
Dimethylamine 0·03 0·001 0·03 0·0008 0·03 0·001 0·85 0·46
Formate 0·02 0·002 0·02 0·002 0·03 0·003 0·11 0·01
Hippurate 0·2 0·04 0·2 0·04 0·2 0·04 0·99 0·99
Trigonelline 0·03 0·01 0·03 0·01 0·04 0·01 0·98 0·57
Trimethylamine N-oxide 0·01 0·002 0·02 0·01 0·01 0·003 0·53 1·00
Butyric acid (μg/ml) 22·7 3·2 24·4 3·1 21·3 3·4 0·99 0·99
* Data were analysed using mixed models with participants as the random effect. All metabolites except for butyric acid were normalised to 1 mM-creatinine. All models were
adjusted for weight and age. Significance was determined as P < 0·05.
Fig. 2. Correlations (r) between angiopoietin-like protein 4 (ANGPTL4) and hypoxia-inducible factor 1α (HIF-1α) mRNA in adipose tissue after control (a, n 15), inulin
(b, n 18) and milk (c, n 17) diets, together with correlations between ANGPTL4 and leptin (LEP) mRNA after control (d, n 17), inulin (e, n 16) and milk (f, n 16) diets.
Expressed in ΔCT and calculated by Pearson’s product moment correlation coefficient.
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gut in addition to regulation of lipid metabolism and storage
by inhibition of lipoprotein lipase. Transwell studies have
shown that ANGPTL4 is secreted to both the apical and baso-
lateral side of enterocytes, indicating that there is a functional
effect of luminal ANGPTL4(28). The gut microbiota has been
implicated in the development of obesity and several mechan-
isms have been proposed, including increased energy har-
vest(16). Given the inhibitory properties of ANGPTL4 on
pancreatic lipase, ANGPTL4 could provide a link between
alterations in the microbiota and increased energy harvest.
In this study, changes in the microbiota composition were
not associated with ANGPTL4 plasma concentration. The
plasma concentration of ANGPTL4 most probably represents
other sources of ANGPTL4 in addition to the gut, such as the
liver or adipose tissue. We have measured plasma ANGPTL4
and adipocyte ANGPTL4 expression but we cannot account
for the production and secretion of ANGPTL4 from the
liver or the gut, which indicates that the observed minor
changes in the microbiota were not sufﬁcient to induce detect-
able changes in ANGPTL4 plasma concentration by changing
the expression of ANGPTL4 in either the intestinal cells or
the liver. Further, recent data from Dijk et al. suggest that
ANGPTL4 is able to inhibit lipoprotein lipase intracellularly
in adipocytes(29), which could explain the lack of effects on
plasma ANGPTL4 concentration. However, analyses of adi-
pose tissue showed that ANGPTL4 mRNA in the adipose tis-
sue was not altered by the dietary interventions, suggesting that
the negative results of the study are a result of a lack of effect
on ANGPTL4.
Adipose tissue ANGPTL4 mRNA was positively correlated
with LEP mRNA in this study; however, the correlation with
HIF-1α mRNA did not reach signiﬁcance. ANGPTL4 is
up-regulated in response to pronounced hypoxia in animals(30)
and in adipocytes(12,31), which could be associated with an
up-regulating effect of ANGPTL4 on angiogenesis.
Plasma NEFA concentration was not associated with
plasma ANGPTL4 concentration in this study. Previous stud-
ies have found a positive association between ANGPTL4
plasma concentration and NEFA concentration(6,11), and the
interaction between NEFA and ANGPTL4 as well as the abil-
ity to affect or respond to NEFA concentration may be one of
the most important functions of ANGPTL4 in relation to lipid
metabolism. The most likely explanation as to why we do not
ﬁnd an association between plasma ANGPTL4 and plasma
NEFA is that the magnitude of the interventions was mark-
edly smaller in the present study, compared with the studies
showing associations between ANGPTL4 and NEFA(6,12).
We did observe that several individual fatty acids were higher
in plasma and faeces after the milk diet compared with the
control diet, which was expected due to the higher dietary con-
tent of these fatty acids in the milk diet. However, there was no
association between ANGPTL4 plasma concentration and
these fatty acids. 12 : 0 and 16 : 0 are components found in
bovine milk and, accordingly, the concentration of these
fatty acids was higher in faecal samples collected after the
milk diet. 16 : 0 was also increased in plasma samples collected
after the milk intervention, compared with the control period.
Previously, 12 : 0 has been shown to up-regulate ANGPTL4 in
in vitro studies(13). However, the increased concentration
observed in the faeces in the present study was not associated
with plasma ANGPTL4 concentration.
In the present study excretion of HCO2
– was found to be
increased in the milk diet. Excretion of HCO2
− has been linked
to increased energy intake(32) or suggested to be a secondary
metabolite resulting from low ﬁbre intake(33). Collectively,
excreted metabolites following a high-inulin or high-milk-fat
dietary intervention did not demonstrate speciﬁc regulation
of fatty acids in this study, which is in accordance with the
other results from the study.
The studywas highly controlled by standardisation of the diets
and the crossover design, which reduced inter-individual vari-
ation by allowing for participants to be compared with them-
selves. A previous study of ANGPTL4 has tested extreme
physiological conditions, such as prolonged fasting or high
amounts of fat(6), whereas this study tested the effects of
ANGPTL4 during a physiologically relevant nutritional inter-
vention for a longer period. The magnitude of the interventions
is a likely cause of the different results of the two studies.
In conclusion, this study does not support that ANGPTL4
can be effectively modiﬁed by moderate nutritional interven-
tions by a modiﬁcation of the gut microbiota composition.
Supplementary material
The supplementary material for this article can be found at
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